ARS Pharmaceuticals Inc.'s (SPRY) flagship product, neffy, has been enjoying strong commercial growth since launch, helped by growing patient awareness and increasing clinician confidence in its efficacy.
Neffy (epinephrine nasal spray) is the first and only FDA- and European Commission-approved needle-free epinephrine treatment for Type I allergic reactions, including anaphylaxis, and represents the first new delivery method for epinephrine in over 35 years. It gained approval in the U.S. and EU in August 2024, with the U.K., Japan, and China following with regulatory approvals in 2025. Approval is expected this quarter in Canada, expanding its global availability.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com